title: Maculopapular skin rashes associated with high-dose chemotherapy: prevalence and risk factors.
abstract: OBJECTIVE
  To determine the prevalence of and risk factors for maculopapular skin rashes associated with high-dose chemotherapy.
  
  
  METHODS
  Observational pilot study.
  
  
  METHODS
  A bone marrow transplant hematology-oncology unit in a private city hospital.
  
  
  METHODS
  Data were collected on 14 patients who developed maculopapular rashes out of 127 patients who received high-dose chemotherapy (purposive sampling).
  
  
  METHODS
  Observation of the distribution and nature of skin rashes in relation to chemotherapy, disease, adjuvant medications, and white blood cell counts.
  
  
  METHODS
  Diseases, chemotherapy protocols and doses, adjuvant medications, and blood counts.
  
  
  RESULTS
  Skin reactions ranged from mild, scattered macular or maculopapular rashes to severe rashes. Patients newly diagnosed with acute myelogenous leukemia (AML) who received induction protocols containing cytarabine had the most rashes, affecting 6 of 11 patients (55%). No rashes were observed on patients treated with the protocol that included high-dose corticosteroids. Patients rarely had recurrence of the rash with further courses of chemotherapy.
  
  
  CONCLUSIONS
  Cytarabine doses higher than 700 mg/m2 may be a cause of maculopapular skin rashes. Patients most at risk were those newly diagnosed with AML who received induction therapy. Corticosteroids may prevent the development of skin rashes.
  
  
  CONCLUSIONS
  No useful nursing strategy exists to prevent, lessen the intensity of, or shorten the course of a delayed hypersensitivity rash. Knowing which patients are most at risk is useful to enable close monitoring and patient and staff education.
authors.affiliation: Bone Marrow Transplant Hematology-Oncology Unit, Wesley Hospital, Auchenflower, Australia. jlwright@bigpond.net.au
authors.forename: Lynette G
authors.initials: LG
authors.lastname: Wright
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003875:Drug Eruptions / Q000453:epidemiology* / Q000276:immunology / Q000451:nursing; D004342:Drug Hypersensitivity / Q000453:epidemiology* / Q000276:immunology / Q000451:nursing; D006801:Humans; D007958:Leukocyte Count; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology* / Q000451:nursing; D009859:Oncology Nursing; D010865:Pilot Projects; D015995:Prevalence; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents